These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22564388)

  • 1. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats.
    Maeda S; Matsui T; Yamagishi S
    Int J Cardiol; 2012 Jun; 158(1):171-3. PubMed ID: 22564388
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vildagliptin].
    Iwamoto Y
    Nihon Rinsho; 2011 May; 69(5):865-70. PubMed ID: 21595273
    [No Abstract]   [Full Text] [Related]  

  • 3. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
    Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
    Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
    Scherbaum WA
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
    [No Abstract]   [Full Text] [Related]  

  • 5. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.
    Matsui T; Nishino Y; Takeuchi M; Yamagishi S
    Pharmacol Res; 2011 May; 63(5):383-8. PubMed ID: 21320599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats.
    Maeda S; Yamagishi S; Matsui T; Nakashima S; Ojima A; Maeda S; Nishino Y; Ishibashi Y; Yoshida Y; Yamakawa R
    Ophthalmic Res; 2013; 50(4):221-6. PubMed ID: 24081217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vildagliptin in clinical practice: a review of literature.
    Banerjee M; Younis N; Soran H
    Expert Opin Pharmacother; 2009 Nov; 10(16):2745-57. PubMed ID: 19874253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
    Pintana H; Apaijai N; Chattipakorn N; Chattipakorn SC
    J Endocrinol; 2013 Jul; 218(1):1-11. PubMed ID: 23591914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
    Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
    [No Abstract]   [Full Text] [Related]  

  • 10. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.
    Glorie LL; Verhulst A; Matheeussen V; Baerts L; Magielse J; Hermans N; D'Haese PC; De Meester I; De Beuf A
    Am J Physiol Renal Physiol; 2012 Sep; 303(5):F681-8. PubMed ID: 22718884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked improvement of elderly postprandial hypotension by dipeptidyl peptidase IV inhibitor.
    Yonenaga A; Ota H; Honda M; Koshiyama D; Yagi T; Hanaoka Y; Yamamoto H; Yamaguchi Y; Iijima K; Akishita M; Ouchi Y
    Geriatr Gerontol Int; 2013 Jan; 13(1):227-9. PubMed ID: 23286563
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S
    Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Between reduction of glucose fluctuations and increased therapeutic adherence: an example of the benefits of vildagliptin in an elderly diabetic patient.
    Chilelli NC; Burlina S; Sartore G; Lapolla A
    Aging Clin Exp Res; 2015 Feb; 27(1):85-7. PubMed ID: 24781833
    [No Abstract]   [Full Text] [Related]  

  • 15. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.
    Kosaraju J; Murthy V; Khatwal RB; Dubala A; Chinni S; Muthureddy Nataraj SK; Basavan D
    J Pharm Pharmacol; 2013 Dec; 65(12):1773-84. PubMed ID: 24117480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes.
    Matikainen N; Taskinen MR
    Diabet Med; 2013 Jun; 30(6):756-7. PubMed ID: 23215876
    [No Abstract]   [Full Text] [Related]  

  • 17. New treatments for type 2 diabetes--the DPP4 inhibitors.
    Gadsby R
    Prim Care Diabetes; 2007 Dec; 1(4):209-11. PubMed ID: 18632049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats.
    El Batsh MM; El Batch MM; Shafik NM; Younos IH
    Eur J Pharmacol; 2015 Dec; 769():297-305. PubMed ID: 26607467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effect of vildagliptin against cerebral ischemia in rats.
    El-Marasy SA; Abdel-Rahman RF; Abd-Elsalam RM
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Oct; 391(10):1133-1145. PubMed ID: 30022232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
    Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.